Vir Biotechnology (NASDAQ:VIR – Free Report) had its target price cut by Morgan Stanley from $27.00 to $15.00 in a research report report published on Friday morning, Benzinga reports. They currently have an equal weight rating on the stock. A number of other equities analysts have also issued reports on VIR. TheStreet lowered shares of […]
Vir Biotechnology (NASDAQ:VIR – Free Report) had its price target cut by Needham & Company LLC from $32.00 to $22.00 in a report published on Thursday, Benzinga reports. They currently have a buy rating on the stock. VIR has been the topic of a number of other research reports. SVB Securities reduced their price objective […]
Vir Biotechnology (NASDAQ:VIR – Free Report) had its target price decreased by The Goldman Sachs Group from $51.00 to $28.00 in a research note published on Friday morning, Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock. Several other equities analysts also recently commented on VIR. Morgan Stanley increased their […]
Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) hit a new 52-week low on Thursday after Morgan Stanley lowered their price target on the stock from $27.00 to $15.00. Morgan Stanley currently has an equal weight rating on the stock. Vir Biotechnology traded as low as $13.16 and last traded at $13.41, with a volume […]
Vir Biotechnology (NASDAQ:VIR – Get Free Report) had its target price lowered by Barclays from $59.00 to $41.00 in a research note issued to investors on Friday, FlyOnTheWall reports. Barclays‘s price objective suggests a potential upside of 222.83% from the stock’s current price. Other analysts have also recently issued reports about the company. Needham & […]